Fluticasone propionate, a topicaily active
after oral administration, has been used in a pilot study for the treatment of mild and moderately active Crohn's disease. Twelve patients received oral fluticasone propionate for three weeks, and the effects were monitored using the Crohn's disease activity index and by`'In granulocyte scanning, assessing inflammation from scan appearances, four day faecal excretion ofradioactivity, and whole body excretion of radioactivity. AU patients completed the trial. No serious side effects were reported. There was a significant fall in Crohn's disease activity index values over the three week treatment period (193 (84) v 122 (51), p<0.01). "`In leucocyte scan images were improved (seven patients) or unchanged (five patients). There was a significant fail in excretion of injected radioactivity calculated from whole body data (28 (21)% v 14 (0.7)%, p<0.05). There were no changes in plasma cortisol values, either basal or synacthen stimulated. Fluticasone propionate is a promising therapeutic agent for Crohn's disease that offers the possibility of controlling inflammation without inducing systemic corticosteroid side effects and which merits evaluation in a double blind trial versus conventional corticosteroids. years, with symptomatic relapse of Crohn's disease, were studied. Eleven of the 12 patients had been treated with prednisolone during previous episodes of relapse. Written informed consent was obtained from each patient. All patients had laboratory evidence ofactive inflammation. Patients were not included if the disease was of sufficient severity to require admission to hospital or had complications that might require surgery. Women who were pregnant or breast feeding and patients with peptic ulcer, active systemic infections, or hypersensitivity to steroids were excluded, as were patients with evidence of renal, hepatic, cardiovascular, metabolic, or endocrine dysfunction or ileostomies. Corticosteroid therapy during the previous 14 days (in excess of 10 mg per day prednisolone equivalent) was also an exclusion criterion.
ASSESSMENT OF DISEASE ACTIVITY Disease activity was assessed by clinical and laboratory parameters. The Crohn's disease activity index (CDAI) was calculated weekly according to standard procedures,2 with a patient diary card being issued to each patient. A "'In white cell scan,`"In faecal excretion, and "'.In whole body counting were carried out in all patients before and after treatment. 34 Pure granulocytes were labelled. For this purpose 102 ml of whole blood were drawn from each patient. Granulocytes were isolated by sedimentation on discontinuous plasma enriched density gradient columns and then labelled with 300 mCi (11 MBq) of "'In-tropolonate.' The patient was then reinjected with the labelled granulocytes and between three and four hours after reinjection, anterior and posterior liver and spleen and anterior and posterior abdominal images were taken using a gamma camera (IGE400A or 400T). At 21 to 24 hours the patient returned for the late images. The images were graded by a qualified nuclear physician, unaware of the other data, as negative (0) "'In WHOLE BODY COUNTING One to three hours after injection of "'.In labelled granulocytes, the patient stood in front of an uncollimated gamma camera (distance of 3.5 m) and was counted over two minutes. The geometric mean of anterior and posterior counts was taken and compared with the counts from an "'In standard, counted at the same distance. The patient returned five to seven days later for the final whole body count. The percentage of the injected "'In which was retained was calculated. The results were expressed as 100 whole body retention (WBR) to indicate the excretion of "'In. A value greater than 10% is abnormal. 
third week of treatment with fluticasone propionate (Fig 1) . The difference was statistically significant (p<0-01).
LABORATORY FINDINGS
The serum C reactive protein was abnormal in six patients before treatment and in five patients after it (median 10 v 2). The mean erythrocyte sedimentation rate was 20 (14.3) mm/hour at the beginning of the trial and 17-0 (11.7) (not significantly different) at the end.
"'In SCAN IMAGING All patients had active inflammation seen on scan before treatment. After treatment with fluticasone propionate, seven patients no longer had abnormal distribution of activity; inflammatory activity was still present in the scans of five patients, one of whom had less activity than previously (Fig 2) .
"'In FAECAL EXCRETION Before the trial abnormal`"In excretion was recorded in six patients, after three weeks of treatment six patients still showed a faecal loss of "'In >2% of the injected dose. Mean values were 17 (32)% v 2.3 (2)%; p=NS.
"'In WBR "'In WBR was abnormal in nine of the 12 active patients at the beginning of the study -that is, in those nine patients, over 10% of injected radioactivity had been lost from the body six days. The mean value for the whole body excretion was 28 (21)%. After fluticasone propionate treatment there was a reduction in excretion in seven patients with an over all mean value of 14 (7)% (p<005) (Fig 3) . New steroid compounds with low systemic bioavailability may provide a major advance in the treatment of inflammatory bowel disease. Such low systemic bioavailability might result from low absorption after oral or rectal administration, rapid first pass metabolism in the gut or liver, or rapid excretion. Several compounds have been or are being assessed. Budesonide," given intrarectally, proved superior to prednisolone enemas in treating active distal ulcerative colitis, using histological and endoscopic assessments. Kumana et al'3 used beclomethasone dipropionate enemas for treatment of inflammatory bowel disease and showed that they were as effective as betamethasone with virtually no effect on the hypothalamo-pituitary-adrenal axis. A later comparative study of beclomethasone dipropionate enemas versus 30 mg prednisolone enemas confirmed the lack of effect of beclomethasone in altering parameters of the hypothalamo-pituitary-adrenal axis after four weeks oftreatment, while prednisolone caused a significant fall in morning plasma cortisol concentration and a reduced increase in cortisol in response to the administration of synacthen.'4 Tixocortol pivalate, derived from cortisol has also been used as an enema'5 and shown not to induce changes in plasma cortisol concentrations. Its therapeutic efficiency was not high, however, and it has not been compared with other steroids.
Fluticasone propionate is a fluorinated glucocorticosteroid. Metabolic studies using labelled and unlabelled compounds systemically in rats showed a distribution and elimination from tissues and plasma very similar to other steroids. The blood clearance of fluticasone propionate can be approximated to liver blood flow, with the hepatic extraction ratio approaching unity. The systemic bioavailability of orally administered fluticasone propionate thus tends towards zero as a consequence of extensive hepatic first pass metabolism. In addition, the drug is poorly absorbed from the gastrointestinal tract. The unabsorbed steroid after oral dosing is therefore available in both the small and large intestine to exert local actions.
In this study an oral daily dose of 20 mg fluticasone propionate seemed effective in treating mild and moderately active small intestinal and colonic Crohn's disease, the effects being apparent within three weeks of treatment.
Significant improvement was shown in clinical symptoms, as measured by the CDAI and quantification of active inflammation from "'In leucocyte scan appearances and whole body excretion data. The results of the faecal excretion data are discussed below. The efficacy of fluticasone propionate is supported by the observation that on follow up 58% of the patients had a relapse within one to six months of stopping the treatment, and required treatment with conventional steroids. The absence of serious side effects and the unchanged plasma cortisol values before and after treatment, confirmed that there was no significant depression of the hypothalamicpituitary-adrenal axis, suggesting that the therapeutic effect was exerted locally.
This outpatient study, however, highlighted a problem in using faecal excretion of "'In to assess changes in inflammation. The results obtained, with in many cases high values of "'In excretion on whole body counting but low values in faecal collections, clearly showed that faecal collections are often incomplete. This study in combination with observations on other patients4 has shown that -whole body retention can be used as a simpler and more accurate technique for quantitating excretion. This method is also more aesthetically acceptable.
It was of interest that the clinical and labelled leucocyte based assessments were not associated with changes in C reactive protein and erythrocyte sedimentation rate values, although neither ofthese were initially strikingly abnormal in this group of patients with mild or moderately active disease. Increases in these parameters reflect enhanced synthesis of acute phase reactants by the liver,'0 and it may be that poorly absorbed steroids have less effect on this aspect of the immune response than they do on local inflammatory responses within the gut.
As this study has suggested that fluticasone propionate may be effective, a randomised trial of this versus prednisolone is now indicated. The value of such a non-absorbable steroid would not only be in the treatment of active disease, but also for maintenance treatment. The European cooperative Crohn's disease study' highlighted the value of 6-methyl prednisolone in a low dose regimen for periods up to two years for patients who entered remission on steroid therapy, and the potential for avoiding systemic side effects during such long term treatment warrants exploration.
